Search This Blog

Thursday, August 20, 2026

AC Immune positive prelim Phase 1 safety, CSF-penetration data, starts Phase 1b

 

AC Immune reports positive preliminary Phase 1 safety and CSF-penetration data for NLRP3 inhibitor ACI-19764

  • Company has begun dosing a cardiovascular risk cohort in the ongoing Phase 1b study of ACI-19764.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)